Abstract Details

Title The Burden of Multiple Sclerosis-Related Spasticity on Indirect Costs and Requirement for Non-Professional Care: Results of a Cross-Sectional Study in the USA

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 217

Objective

Background BACKGROUND: Multiple sclerosis (MS) is a chronic, often progressive disease, frequently accompanied by functional impairment due to spasticity. It is hypothesized that as severity of spasticity increases there is a corresponding impact on indirect costs and the need for the support of a non-professional caregiver.

Design/Methods DESIGN/METHODS: Data were drawn from the Adelphi MS Disease Specific Programme, a cross-sectional research programme in the USA of 1641 consulting MS patients. Preliminary analysis using ANOVA with Bonferroni-corrected t-tests and Fisher's Exact Test with Bonferroni corrections established the most appropriate split was between the physician-assessed mild and moderate spasticity levels. Double robust estimates (combining propensity scoring with weighted regression) were subsequently calculated to show the differences in indirect costs including non-professional care between patients with moderate or severe spasticity and those with no or mild spasticity. Confounding factors included Expanded Disability Severity Scale (EDSS), gender, age, body mass index, concomitant conditions, compliance and MS type.

Results RESULTS: Complete data were obtained for 439 patients. Compared with patients with no or mild spasticity, presence of moderate or severe spasticity was associated with an additional 19.7 days off work in the previous 12 months (p<0.01). An additional 4.8% of moderate/severe spasticity patients reported changes at the workplace to allow for wheelchair access (p<0.01) and 4.3% had additional furniture/equipment provided to allow access at work (p<0.01). Mobility aids were used by an additional 16.4% of moderate/severe spasticity patients (p<0.05); an additional 8.1% required a wheelchair (p<0.05), and an additional 11.1% required a non-professional caregiver (p<0.05).

Conclusions CONCLUSIONS: MS patients with moderate/severe spasticity increase the burden in the workplace, on their family/friends and requirement for walking aids. This may indicate an increased societal need to address MS patients with moderate to severe spasticity.

Authors/Disclosures
Randall T. Schapiro, MD, FAAN PRESENTER	No disclosure on file
Daniel R. Wynn, MD (Consultants in Neurology, Ltd.)	Dr. Wynn has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mylan. Dr. Wynn has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Wynn has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Wynn has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Wynn has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TEVA. The institution of Dr. Wynn has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Banner Life. Dr. Wynn has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Biogen. The institution of Dr. Wynn has received research support from Novartis. The institution of Dr. Wynn has received research support from Sanofi. The institution of Dr. Wynn has received research support from Adamas Pharmaceutics. The institution of Dr. Wynn has received research support from EMD Serono. The institution of Dr. Wynn has received research support from Roche. Dr. Wynn has a non-compensated relationship as a Director, Consultants in Neurology Comprehensive Care Center with National MS Society that is relevant to AAN interests or activities.
Dmitri V. Lissin, MD (Scilex Holding)	Dr. Lissin has received personal compensation in the range of $500,000-$999,999 for serving as a Chief Medical Officer with Scilex Holding .
Ahmad M. Al-Sabbagh, MD (Avion Pharmaceuticals)	Dr. Al-Sabbagh has nothing to disclose.
Eddie Jones, BA	Eddie Jones, BA has nothing to disclose.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��